동반진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global companion diagnostic market size is expected to reach USD 28.18 Billion in 2034 from USD 10.58 Billion in 2025, growing at a CAGR of 11.5 during 2026-2034.This market is expanding rapidly due to the growing adoption of personalized medicine and targeted therapies in healthcare. Companion diagnostics are essential tools that help identify patients who are most likely to benefit from specific treatments, particularly in oncology and other complex diseases. The increasing prevalence of chronic diseases and the need for more precise and effective treatment options are driving market growth. Advances in molecular biology and genomics are enabling the development of highly accurate diagnostic tests that support personalized treatment strategies.

Growth drivers include the rising investment in research and development by pharmaceutical and biotechnology companies. The collaboration between diagnostic developers and drug manufacturers is accelerating the introduction of new companion diagnostic products. Regulatory support for personalized medicine and the approval of targeted therapies are also contributing to market expansion. Additionally, the increasing use of advanced technologies such as next-generation sequencing and biomarker analysis is enhancing the accuracy and reliability of diagnostic tests.

Looking ahead, the companion diagnostic market is expected to witness significant advancements in technology and application. Companies are likely to focus on developing multi-gene and multiplex diagnostic tests that can provide comprehensive insights into patient conditions. The integration of artificial intelligence and data analytics will further improve diagnostic accuracy and decision-making. As healthcare systems continue to shift toward personalized and precision medicine, companion diagnostics will play a critical role in optimizing treatment outcomes and reducing healthcare costs.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Technology

• Polymerase Chain Reaction
• Immunohistochemistry
• In-situ Hybridization
• Next Generation Gene Sequencing
• Others

By Indication

• Cancer
• Neurological Diseases
• Infectious Diseases
• Others

By End-user

• Pharmaceutical & Biopharmaceutical Companies
• Reference Laboratories
• Contract Research Organizations (CROs)

COMPANIES PROFILED

• Abbott, F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Illumina Inc., Guardant Health, Thermo Fisher Scientific Inc., Biomerieux, Qiagen, Myriad Genetics Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COMPANION DIAGNOSTIC MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Polymerase Chain Reaction Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunohistochemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. In-situ Hybridization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Next Generation Gene Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COMPANION DIAGNOSTIC MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Neurological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COMPANION DIAGNOSTIC MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Pharmaceutical & Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Reference Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Contract Research Organizations (CROs) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COMPANION DIAGNOSTIC MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Technology
  • 7.2.2 By Indication
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Technology
  • 7.3.2 By Indication
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Technology
  • 7.4.2 By Indication
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Technology
  • 7.5.2 By Indication
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Technology
  • 7.6.2 By Indication
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL COMPANION DIAGNOSTIC INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Abbott
  • 9.2.2 F. Hoffmann-La Roche Ltd
  • 9.2.3 Agilent Technologies Inc
  • 9.2.4 Illumina Inc
  • 9.2.5 Guardant Health
  • 9.2.6 Thermo Fisher Scientific Inc
  • 9.2.7 Biomerieux
  • 9.2.8 Qiagen
  • 9.2.9 Myriad Genetics Inc